Clinical Trial Update: Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa [Phase 3]

View source ↗

Summary

Open-label Phase 3 trial evaluating safety and efficacy of adalimumab in hidradenitis suppurativa has completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Hidradenitis Suppurativa | Phase 3 | Status: COMPLETED | Results posted: 2017-09-05